Cited by 279Schizophrenia research and treatmentNeurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Schizophrenia: More dopamine, more D 2 receptors

Open access

Seeman, Philip, Kapur, Shitij·2000·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.97.14.7673PMC PMC33999

Open this paper in CoChat — free account

Abstract

Schizophrenia is a major therapeutic challenge of modern medicine, and one of the last frontiers of brain research. The illness is defined by delusions, hallucinations, disorganized behavior, and cognitive difficulties such as memory loss. It occurs in ≈1% of the world population and usually first appears in early adulthood. Although antipsychotic medications have dramatically improved the lives of patients with schizophrenia, the causes of the illness remain unknown. Of the many contemporary theories of schizophrenia, the most enduring has been the dopamine hypothesis. As originally put by Van Rossum in 1967 (ref. 1, p. 321), “When the hypothesis of dopamine blockade by neuroleptic agents can be further substantiated, it may have fargoing consequences for the pathophysiology of schizophrenia. Overstimulation of dopamine receptors could be part of the aetiology … [emphasis added].” Indeed, this speculative sentence by Van Rossum foreshadows the title of the important work by Abi-Dargham et al . (2) in this issue of PNAS: “Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.” The discovery of the antipsychotic/dopamine receptor (3, 4), now commonly known as the dopamine D2 receptor, led to repeated confirmation that it is the primary site of action for all antipsychotics (3–5), including clozapine and quetiapine (6). All these drugs have different potencies at the receptor. The potency depends on the drug's dissociation constant at D2, which, in turn, relates to the rate of release of the drug from the D2 receptor. For example, the dopamine D2 receptor releases clozapine and quetiapine more rapidly than it does any of the other antipsychotic drugs (7, 8). Given the tight correlation between the clinical potency and the D2-blocking action of the antipsychotic medications, dopamine overactivity could be the common denominator in the …

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.97.14.7673

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Self-citation
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Clinical and Theoretical Implications of 5-HT2 and D2 Receptor Occupancy of Clozapine, Risperidone, and Olanzapine in Schizophrenia
Kapur, S., Zipursky, R. B., & Remington, G. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.286 · Cited by 711
Self-citation
Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
Seeman, P. M., Chau-Wong, M., Tedesco, J., & Wong, K. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.11.4376 · Cited by 702
Self-citation
Neuro‐Psychopharmacology
(1962) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1962.tb27008.x · Cited by 594
D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients
Farde, L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150013003 · Cited by 529
Location of a Major Susceptibility Locus for Familial Schizophrenia on Chromosome 1q21-q22
Brzustowicz, L. M., Hodgkinson, K. A., Chow, E. W. C., Honer, W. G., & Bassett, A. S. (2000) · Science · doi:10.1126/science.288.5466.678 · Cited by 516
Properties of [3H]Haloperidol and [3H]Dopamine Binding Associated with Dopamine Receptors in Calf Brain Membranes
Burt, D. R., Creese, I., & Snyder, S. H. (1976) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10800-6 · Cited by 482

Show all 22 references

Research works printed but not linked: 7

J Van Rossum Neuropsychopharmacology, Proceedings Fifth Collegium Internationale Neuropsychopharmacologicum, eds H Brill, J Cole, P Deniker, H Hippius, P B Bradley (Excerpta Medica, Amsterdam), pp. 321–329 (1967).
D R Burt, I Creese, S H Snyder Mol Pharmacol 12, 800–812 (1976).
Kapur S. Zipursky R. Jones C. Shammi C. S. Remington G. & Seeman P. (2000) Arch. Gen. Psychiatry in press.
S Kapur, P Seeman J Psychiatr Neurosci 25, 161–166 (2000).
P Seeman Neuropsychopharmacology 7, 261–284 (1992).
A C Barton, L E Black, D R Sibley Mol Pharmacol 39, 650–658 (1991).
M Itokawa, M Toru, K Ito, H Tsuga, K Kameyama, T Haga, T Arinami, H Hamaguchi Mol Pharmacol 49, 560–566 (1996).

Sorted by citations

Items 101–200 of 279

Glutamate, obsessive–compulsive disorder, schizophrenia, and the stability of cortical attractor neuronal networks
Rolls, E. T. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.017 · Cited by 39
Consensus on potential biomarkers developed for use in clinical tests for schizophrenia
Lin, P., Sun, J., Lou, X., Li, D., Shi, Y., Li, Z., Ma, P., Li, P., Chen, S., Jin, W., et al. (2022) · General Psychiatry · doi:10.1136/gpsych-2021-100685 · Cited by 39
Dopaminergic Pathway Gene Polymorphisms and Genetic Susceptibility to Schizophrenia among North Indians
Srivastava, V., Deshpande, S. N., & Thelma, B. K. (2009) · Neuropsychobiology · doi:10.1159/000265131 · Cited by 38
Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia
Amar, S., Shaltiel, G., Mann, L., Shamir, A., Dean, B., Scarr, E., Bersudsky, Y., Belmaker, R. H., & Agam, G. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007948 · Cited by 38
Managing Values: A Systematic Approach to Business Ethics.
Kirrane, D. E. (1990) · Training and development journal · Cited by 37
Schizophrenia: elevated mRNA for dopamine D2Longer receptors in frontal cortex
Tallerico, T., Novak, G., Liu, I. S. C., Ulpian, C., & Seeman, P. M. (2001) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00293-x · Cited by 36
Self-citation
Dopamine Receptor Excess and Mouse Madness
Snyder, S. H. (2006) · Neuron · doi:10.1016/j.neuron.2006.02.002 · Cited by 36
Dopamine Receptor Interacting Proteins: Targeting Neuronal Calcium Sensor-1/D2 Dopamine Receptor Interaction for Antipsychotic Drug Development
Kabbani, N., Woll, M. P., Nordman, J. C., & Levenson, R. G. (2011) · Current Drug Targets · doi:10.2174/138945012798868515 · Cited by 31
Microtubule‐associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission
Bouvrais‐Veret, C., Weiss, S., Hanoun, N., Andrieux, A., Schweitzer, A., Job, D., Hamon, M., Giros, B., & Martres, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05025.x · Cited by 40
Adverse extrapyramidal effects in four horse given fluphenazine decanoate
Baird, J. D., Arroyo, L. G., Vengušt, M., McGurrin, M. K. J., Rodriguez‐Palacios, A., Kenney, D. G., Aravagiri, M., & Maylin, G. A. (2006) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.229.1.104 · Cited by 32
RIT2 Polymorphisms: Is There a Differential Association?
Emamalizadeh, B., Jamshidi, J., Movafagh, A., Ohadi, M., Khaniani, M. S., Kazeminasab, S., Biglarian, A., Taghavi, S., Motallebi, M., Fazeli, A., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9815-4 · Cited by 35
Assessing the construct validity of aberrant salience
Schmidt, K. (2009) · Frontiers in Behavioral Neuroscience · doi:10.3389/neuro.08.058.2009 · Cited by 33
Movement abnormalities and psychotic-like experiences in childhood: markers of developing schizophrenia?
MacManus, D., Laurens, K. R., Walker, E. F., Brasfield, J. L., Riaz, M. A., & Hodgins, S. (2011) · Psychological Medicine · doi:10.1017/s0033291711001085 · Cited by 31
Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development
Howell, K. R., & Law, A. J. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.08.036 · Cited by 30
Butyl Methacrylate-Co-Ethylene Glycol Dimethacrylate Monolith for Online in-Tube SPME-UHPLC-MS/MS to Determine Chlopromazine, Clozapine, Quetiapine, Olanzapine, and Their Metabolites in Plasma Samples
Beloti, L. G. M., Miranda, L. F. C., & Queiroz, M. E. C. (2019) · Molecules · doi:10.3390/molecules24020310 · Cited by 30
Active inference, morphogenesis, and computational psychiatry
Pio‐Lopez, L., Kuchling, F., Tung, A., Pezzulo, G., & Levin, M. G. (2022) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2022.988977 · Cited by 29
Immersion in altered experience: An investigation of the relationship between absorption and psychopathology
Rosen, C., Jones, N., Chase, K. A., Melbourne, J. K., Grossman, L. S., & Sharma, R. P. (2017) · Consciousness and Cognition · doi:10.1016/j.concog.2017.01.015 · Cited by 29
Synapsin II gene expression in the dorsolateral prefrontal cortex of brain specimens from patients with schizophrenia and bipolar disorder: effect of lifetime intake of antipsychotic drugs
Tan, M. L., Dyck, B. A., Gabriele, J. P., Daya, R. P., Thomas, N., Sookram, C. D., Basu, D., Ferro, M. A., Chong, V. Z., & Mishra, R. K. (2013) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.6 · Cited by 27
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
Beyaert, M. G. R., Daya, R. P., Dyck, B. A., Johnson, R. L., & Mishra, R. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.010 · Cited by 28
Alteration of conditioned emotional response and conditioned taste aversion after neonatal ventral hippocampus lesions in rats
Angst, M.-J., de Macedo, C. E. A., Guiberteau, T., & Sandner, G. (2007) · Brain Research · doi:10.1016/j.brainres.2007.01.093 · Cited by 29
To Do or Not to Do: Dopamine, Affordability and the Economics of Opportunity
Beeler, J. A., & Mourra, D. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00006 · Cited by 28
Mechanism of action of clozapine in the context of dopamine D1-D2 receptor hetero-dimerization--a working hypothesis.
Dziedzicka‐Wasylewska, M., Faron‐Górecka, A., Górecki, A., & Kuśemider, M. (2008) · PubMed · Cited by 23
Multiple Adenosine-Dopamine (A2A-D2 Like) Heteroreceptor Complexes in the Brain and Their Role in Schizophrenia
Borroto‐Escuela, D. O., Ferraro, L., Narváez, M., Tanganelli, S., Beggiato, S., Liu, F., Rivera, A., & Fuxé, K. (2020) · Cells · doi:10.3390/cells9051077 · Cited by 23
Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels
Ochi, R., Plitman, E., Patel, R., Tarumi, R., Iwata, Y., Tsugawa, S., Kim, J., Honda, S., Noda, Y., Uchida, H., et al. (2022) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.210113 · Cited by 25
Cerebrospinal fluid monoamine metabolite levels in human newborn infants born in winter differ from those born in summer
Chotai, J., Murphy, D. L., & Constantino, J. N. (2006) · Psychiatry Research · doi:10.1016/j.psychres.2005.11.008 · Cited by 23
Altered neurotrophin receptor function in the developing prefrontal cortex leads to adult-onset dopaminergic hyperresponsivity and impaired prepulse inhibition of acoustic startle
Rajakumar, N., Leung, L.-W. S., Ma, J., Rajakumar, B. S. J., & Rushlow, W. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.12.015 · Cited by 23
The Caenorhabditis elegans D2-like dopamine receptor DOP-2 physically interacts with GPA-14, a Gαi subunit
Pandey, P., & Dhillon, H. S. (2012) · Journal of Molecular Signaling · doi:10.1186/1750-2187-7-3 · Cited by 23
Functional effects of cannabinoids during dopaminergic specification of human neural precursors derived from induced pluripotent stem cells
Stanslowsky, N., Jahn, K., Venneri, A., Naujock, M., Haase, A., Martin, U., Frieling, H., & Wegner, F. (2016) · Addiction Biology · doi:10.1111/adb.12394 · Cited by 22
Astrocytic basic fibroblast growth factor expression in dopaminergic regions after perinatal anoxia
Flores, C., Stewart, J., Salmaso, N., Zhang, Y., & Boksa, P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01363-x · Cited by 23
The Therapeutic Potential of Ketogenic Diet Throughout Life: Focus on Metabolic, Neurodevelopmental and Neurodegenerative Disorders
Kraeuter, A.-K., Guest, P. C., & Sarnyai, Z. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-25650-0_5 · Cited by 24
The Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia
Nasyrova, R., Khasanova, A. K., Altynbekov, K. S., Asadullin, A., Markina, E. A., Gayduk, A., Shipulin, G., Petrova, M. M., & Shnayder, N. (2022) · Nutrients · doi:10.3390/nu14235142 · Cited by 16
Dopaminergic Modulation of Excitatory Transmission in the Anterior Cingulate Cortex of Adult Mice
Darvish-Ghane, S., Yamanaka, M., & Zhuo, M. (2016) · Molecular Pain · doi:10.1177/1744806916648153 · Cited by 24
Schizotypy trait and striatal dopamine receptors in healthy volunteers
Chen, K. C., Lee, I. H., Yeh, T. L., Chiu, N. T., Chen, P. S., Yang, Y. K., Lu, R.-B., & Chen, C. C. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2011.07.003 · Cited by 21
Dopaminergic gene polymorphisms and cognitive function in a north Indian schizophrenia cohort
Kukshal, P., Kodavali, V. C., Srivastava, V., Wood, J. A., McClain, L. L., Triptish Bhatia, A., Bhagwat, A. M., Deshpande, S. N., Nimgaonkar, V. L., & Thelma, B. K. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.07.007 · Cited by 22
Are persistent delusions in schizophrenia associated with aberrant salience?
Abboud, R., Roiser, J. P., Khalifeh, H., Ali, S., Harrison, I., Killaspy, H. T., & Joyce, E. M. (2016) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2016.04.002 · Cited by 23
Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebusmonkeys
Madsen, M. V., Peacock, L., Werge, T. M., & Andersen, M. B. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063816 · Cited by 20
Decreased [3H]spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study
Zavitsanou, K., & Huang, X. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00533-4 · Cited by 20
Gender-Specific Associations betweenCHGBGenetic Variants and Schizophrenia in a Korean Population
Shin, J.-G., Kim, J., Park, C. S., Kim, B., Kim, J., Choi, I., Hwang, J., Shin, H. D., & Woo, S.-I. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.619 · Cited by 19
The state of the art of nanopsychiatry for schizophrenia diagnostics and treatment
Radaic, A., & Martins‐de‐Souza, D. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102222 · Cited by 21
In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis
Mejia-Gutierrez, M., Vásquez-Paz, B. D., Fierro, L., & Maza, J. R. (2021) · ACS Omega · doi:10.1021/acsomega.0c05984 · Cited by 18
Dopaminergic function in relation to genes associated with risk for schizophrenia
Moran, P. M., O’Tuathaigh, C. M. P., Papaleo, F., & Waddington, J. L. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63425-2.00004-0 · Cited by 19
Neuroimaging as a Window Into the Pathophysiological Mechanisms of Schizophrenia
Kraguljac, N. V., & Lahti, A. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.613764 · Cited by 17
Brain mechanisms of visual encoding and working memory in psychometrically identified schizotypal individuals and after acute administration of haloperidol
Kopp, B., Wolff, M., Hruška, C. A., & Reischies, F. M. (2002) · Psychophysiology · doi:10.1111/1469-8986.3940459 · Cited by 18
Impedance-based dopamine detection neural probe utilizing dopamine antibody: Real-time quantification of dopamine
Park, D., Ahn, D., Choi, J., Kim, J., Song, M., Wang, P., Piao, H., Park, S., Jo, E. A., Kim, H. Y., et al. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117803 · Cited by 17
Acupuncture as Add-On Treatment of the Positive, Negative, and Cognitive Symptoms of Patients with Schizophrenia: A Systematic Review
van den Noort, M., Yeo, S., Lim, S., Lee, S., Staudte, H., & Bosch, P. (2018) · Medicines · doi:10.3390/medicines5020029 · Cited by 17
A Potential Interface between the Kynurenine Pathway and Autonomic Imbalance in Schizophrenia
Büki, A., Kékesi, G., Horváth, G., & Vécsei, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810016 · Cited by 18
The H3antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers
Othman, A. A., Haig, G. M., Florian, H., Locke, C. S., Gertsik, L., & Dutta, S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12281 · Cited by 17
The impact of weight gain associated with atypical antipsychotic use in schizophrenia
Chue, P. S., & Cheung, R. M. C. (2004) · Acta Neuropsychiatrica · doi:10.1111/j.0924-2708.2004.00067.x · Cited by 17
Regulation of central dopamine-2 receptor sensitivity by a proportional control thermostat in humans.
Schwartz, P., & Erk, S. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.03.004 · Cited by 23
Subclinical Psychotic Experiences in Healthy Young Adults: Associations with Stress and Genetic Predisposition
Bruenig, D., White, M. J., Young, R. M., & Voisey, J. (2014) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2014.0111 · Cited by 16
Calcium-related signaling pathways contributed to dopamine-induced cortical neuron apoptosis
Zhang, L., Yang, H. M., Zhao, H., & Zhao, C. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.11.021 · Cited by 16
Translocation of AIF in the human and rat striatum following protracted haloperidol, but not clozapine treatment
Skoblenick, K. J., Castellano, J. M., Rogoza, R. M., Dyck, B. A., Thomas, N., Gabriele, J. P., Chong, V. Z., & Mishra, R. K. (2006) · APOPTOSIS · doi:10.1007/s10495-006-5698-6 · Cited by 16
Dopamine and schizophrenia--proof at last?
Harrison, P. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02710-0 · Cited by 19
Spatial and Temporal Abnormalities of Spontaneous Fixational Saccades and Their Correlates With Positive and Cognitive Symptoms in Schizophrenia
Liu, X., Li, Y., Xu, L., Zhang, T., Cui, H., Wei, Y., Xia, M., Su, W., Tang, Y., Tang, X., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad039 · Cited by 15
Persistent Metabolic Changes Are Induced by 24 h Low-Dose Lead (Pb) Exposure in Zebrafish Embryos
Cooper, G., North, R. J., Hunt-Smith, T., Larson, J. D., Rennie, M., Bailey, M. L., Scarlata, S., Merzdorf, C., & Bothner, B. B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031050 · Cited by 15
Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review
Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025) · Pharmaceuticals · doi:10.3390/ph18020185 · Cited by 14
A polygenic score indexing a DRD2-related co-expression network is associated with striatal dopamine function
D’Ambrosio, E., Pergola, G., Pardiñas, A. F., Dahoun, T., Veronese, M., Sportelli, L., Taurisano, P., Griffiths, K., Jauhar, S., Rogdaki, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16442-6 · Cited by 14
Neonatal basolateral amygdala lesions affect monoamine and cannabinoid brain systems in adult rats
Bouwmeester, H., Gerrits, M. A. F. M., Roozemond, J. G., Snapper, J., Ronken, E., Kruse, C. G., Westenberg, H. G. M., & van Ree, J. M. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007346 · Cited by 14
Biased signaling via serotonin 5-HT2A receptor: From structural aspects to in vitro and in vivo pharmacology
Jastrzębski, M. K., Wójcik, P., Grudzińska, A., Andreozzi, G., Vetrò, T., Asim, A., Mudgal, A., Czapiński, J., Wróbel, T. M., Bartuzi, D., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.002 · Cited by 15
Atypical Antipsychotic Drug Ziprasidone Protects against Rotenone-Induced Neurotoxicity: An In Vitro Study
Terada, K., Murata, A., Toki, E., Goto, S., Yamakawa, H., Setoguchi, S., Watase, D., Koga, M., Takata, J., Matsunaga, K., et al. (2020) · Molecules · doi:10.3390/molecules25184206 · Cited by 13
Evidence for Alternative Splicing of a Dopamine D2 Receptor in a Teleost
Popesku, J. T., Navarro‐Martín, L., & Trudeau, V. L. (2011) · Physiological and Biochemical Zoology · doi:10.1086/658290 · Cited by 13
Meta-Type Analysis of Dopaminergic Effects on Gene Expression in the Neuroendocrine Brain of Female Goldfish
Popesku, J. T., Martyniuk, C. J., & Trudeau, V. L. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00130 · Cited by 13
Neurostructural, Neurofunctional, and Clinical Features of Chronic, Untreated Schizophrenia: A Narrative Review
Tang, B., Li, Y., Strawn, J. R., Zhang, W., & Lui, S. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae152 · Cited by 12
Expression of Dopamine D1−4 and Serotonin 5-HT1A-3A Receptors in Blood Mononuclear Cells in Schizophrenia
Wysokiński, A., Kozłowska, E., Szczepocka, E., Łucka, A., Agier, J., Brzezińska‐Błaszczyk, E., & Sobierajska, K. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.645081 · Cited by 12
Structure and dynamics of DRD4 bound to an agonist and an antagonist usingin silicoapproaches
Jatana, N., Thukral, L., & Latha, N. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24716 · Cited by 12
Hyperthermia Caused by Drug Interactions and Adverse Reactions
Paden, M. S., Franjic, L., & Halcomb, S. E. (2013) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2013.07.003 · Cited by 12
Alterations in ventral and dorsal striatal allosteric A2AR-D2R receptor-receptor interactions after amphetamine challenge: Relevance for schizophrenia
Pintšuk, J., Borroto‐Escuela, D. O., Lai, T. K. Y., Liu, F., & Fuxé, K. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.10.027 · Cited by 12
PNA-Based Multivalent Scaffolds Activate the Dopamine D2 Receptor
Dix, A. V., Conroy, J., Rosenker, K. M. G., Sibley, D. R., & Appella, D. H. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500478m · Cited by 11
Dopamine Receptors and the Treatment of Schizophrenia
Ginovart, N., & Kapur, S. (2009) · The Receptors · doi:10.1007/978-1-60327-333-6_16 · Cited by 11
Self-citation
Decreased expression of a 40-kDa catecholamine-regulated protein in the ventral striatum of schizophrenic brain specimens from the Stanley Foundation Neuropathology Consortium
Gabriele, J. P., CHONG, V., PONTORIERO, G., & MISHRA, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.03.025 · Cited by 11
Susceptibility of persons with schizophrenia to extreme heat: A critical review of physiological, behavioural, and social factors
Kirby, N. V., Tetzlaff, E. J., Kidd, S. A., Brown, E. E., Bezgrebelna, M., Yoon, L., Henderson, S. B., & Kenny, G. P. (2025) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2025.179965 · Cited by 13
MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats
Castellano, J. M., Batrynchuk, J., Dolbeare, K., Verma, V., Mann, A., Skoblenick, K. J., Johnson, R. L., & Mishra, R. K. (2007) · Peptides · doi:10.1016/j.peptides.2007.07.026 · Cited by 10
Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders
Harris, S., & Urs, N. M. (2021) · CNS Drugs · doi:10.1007/s40263-021-00796-y · Cited by 10
Role of a Gαi2 protein splice variant in the formation of an intracellular dopamine D2 receptor pool
López‐Aranda, M. F., Acevedo, M. J., Gutiérrez, A., Koulen, P., & Khan, Z. U. (2007) · Journal of Cell Science · doi:10.1242/jcs.005611 · Cited by 10
Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain
Hur, K., Kim, S., Ma, S., Lee, B., Ko, Y., Seo, J., Kim, S., Kim, Y., Sung, S., Lee, Y., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15528 · Cited by 9
Cognitive Effects of Nicotine
Sofuoglu, M., Herman, A. I., Robinson, C. D., & Waters, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00012-5 · Cited by 8
Mechanisms of Action of Atypical Antipsychotics
Cañas, F. (2005) · CNS Spectrums · doi:10.1017/s1092852900025165 · Cited by 9
An Introduction to CNS-Resident Microglia: Definitions, Assays, and Functional Roles in Health and Disease
Davis, D. S., & Carson, M. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4729-0_1 · Cited by 8
Uncoupling DISC1 × D2R Protein-Protein Interactions Facilitates Latent Inhibition in Disc1-L100P Animal Model of Schizophrenia and Enhances Synaptic Plasticity via D2 Receptors
Lipina, T. V., Beregovoy, N. A., Tkachenko, A. A., Петрова, Е. С., Starostina, M. V., Zhou, Q., & Li, S. (2018) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2018.00031 · Cited by 8
Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson’s disease: A Preliminary Study
Gupta, A. K., Rani, K., Swarnkar, S., Kumar, G. K., Khan, M. I., Pokhriyal, R., Kumar, D. R., Goyal, V., Tripathi, M., Gupta, R., et al. (2018) · Journal of Central Nervous System Disease · doi:10.1177/1179573518803585 · Cited by 8
Simulation-based optimisation of the PET data processing for Partial Saturation Approach protocols
Wimberley, C., Angelis, G. I., Boisson, F., Callaghan, P. D., Fischer, K., Pichler, B. J., Meikle, S. R., Grégoire, M., & Reilhac, A. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.04.010 · Cited by 8
Striatal dopamine receptor plasticity in neurotensin deficient mice
Chastain, L. G., Qu, H., Bourke, C. H., Iuvone, P. M., Dobner, P. R., Nemeroff, C. B., & Kinkead, B. L. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.11.014 · Cited by 9
Basal ganglia volumetric changes in psychotic spectrum disorders
Liu, C., Cao, B., Yu, R., & Sim, K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.05.048 · Cited by 8
The development of paliperidone nanocrystals for the treatment of schizophrenia
Lhaglham, P., Jiramonai, L., Liang, X.-J., Liu, B.-C., & Li, F.-Z. (2024) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ad8fe7 · Cited by 5
Antipsychotic drug use is correlated with CRP40/mortalin mRNA expression in the dorsolateral prefrontal cortex of human postmortem brain specimens
Gabriele, J. P., Pontoriero, G. F., Thomas, N., Ferro, M. A., Mahadevan, G., MacCrimmon, D. J., Pristupa, Z. B., & Mishra, R. K. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.039 · Cited by 7
Dehydroepiandrosterone (DHEA) and DHEA Sulfate: Roles in Brain Function and Disease
Quinn, T., Robinson, S. R., & Walker, D. W. (2018) · InTech eBooks · doi:10.5772/intechopen.71141 · Cited by 10
The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study
Smigielski, L., Wotruba, D., Treyer, V., Rössler, J., Papiol, S., Falkai, P., Grünblatt, E., Walitza, S., & Wulf Rössler, A. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab034 · Cited by 7
Analysis of Acute and Chronic Methamphetamine Treatment in Mice on Gdnf System Expression Reveals a Potential Mechanism of Schizophrenia Susceptibility
Casserly, L., Garton, D. R., Montaño-Rodriguez, A., & Andressoo, J. (2023) · Biomolecules · doi:10.3390/biom13091428 · Cited by 7
Structural imaging of schizophrenia
Whitford, T. J., Kubicki, M. R., & Shenton, M. E. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782091.002 · Cited by 7
The neuromuscular basis of functional impairment in schizophrenia: A scoping review
Raj, V. K., Stogios, N., Agarwal, S. M., & Cheng, A. J. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.09.002 · Cited by 6
Direct effects of antipsychotics on potassium channels
Zhuang, W., Mun, S., & Park, W. S. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151344 · Cited by 6
Convenient synthesis of 18 F‐radiolabeled R‐(−)‐N‐ n ‐propyl‐2‐(3‐fluoropropanoxy‐11‐hydroxynoraporphine
Sromek, A. W., Zhang, S., Akurathi, V., Packard, A. B., Li, W., Alagille, D., Morley, T. J., Baldwin, R. M., Tamagnan, G. D., & Neumeyer, J. L. (2014) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3246 · Cited by 6
Partial Dopamine D2/Serotonin 5-HT1A Receptor Agonists as New Therapeutic Agents
Etiévant, A., Betry, C., & Haddjeri, N. (2010) · The Open Neuropsychopharmacology Journal · Cited by 6
Dopamine D1 Receptor (D1R) Expression Is Controlled by a Transcriptional Repressor Complex Containing DISC1
Suh, Y., Noh, S.-J., Lee, S., Suh, B. K., Lee, S. B., Choi, J., Jeong, J., Kim, S., & Park, S. K. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1566-6 · Cited by 6
On and Off switches in the brain
Moustafa, A. A. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00114 · Cited by 7
Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19Preprint
Le, B. L., Andreoletti, G., Oskotsky, T., Vallejo-Gracia, A., Rosales, R., Yu, K., Kosti, I., Leon, K. E., Bunis, D. G., Li, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.23.352666 · Cited by 6
Combination of In Vivo [123I]FP-CIT SPECT and Microdialysis Reveals an Antipsychotic Drug Haloperidol-induced Synaptic Dopamine Availability in the Rat Midbrain and Striatum
Park, S. H., Song, Y. S., Moon, B. S., Lee, B. C., Park, H. S., & Kim, S. E. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.5.602 · Cited by 5
Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia
Li, N., Li, Y., Yu, T. Y., Gou, M., Chen, W., Wang, X., Tong, J., Song, C., Tan, S., Wang, Z., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.04.017 · Cited by 6
4D-QSAR Model for Compounds with Binding Affinity Towards Dopamine D2 Receptors
Silva, D. R., Ramalho, T. C., & da Cunha, E. F. F. (2013) · Letters in Drug Design & Discovery · doi:10.2174/1570180810666131113213448 · Cited by 5
The mitochondria in schizophrenia with 22q11.2 deletion syndrome: From pathogenesis to therapeutic promise of targeted natural drugs
Xiong, Z., Wang, H., Qu, Y., Peng, S., He, Y., Yang, Q., Xu, X., Lv, D., Liu, Y., Xie, C., et al. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110831 · Cited by 5

Authors: Seeman, P., & Kapur, S.
Affiliations: University of Toronto (CA)
ORCID: Seeman, Philip
Kapur, Shitij
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2000-07-05
Volume: 97
Issue: 14
Pages: 7673-7675
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.97.14.7673
PMC: PMC33999
OpenAlex: W2022725791
Cited by: 279
References: 22
Citations by year: 2026: 1 · 2025: 14 · 2024: 8 · 2023: 9 · 2022: 10 · 2021: 15 · 2020: 5 · 2019: 12 · 2018: 9 · 2017: 4 · 2016: 11 · 2015: 15 · 2014: 19 · 2013: 14 · 2012: 13
FWCI: 6.28
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: schizophrenia, dopamine hypothesis, dopamine D2 receptor, receptor occupancy, antipsychotic drugs, clozapine, quetiapine, receptor dissociation constant, schizophrenia pathophysiology
MeSH terms: Benzamides, Dopamine, Models, Biological, Psychotic Disorders, Pyrrolidines, Schizophrenia, Receptors, Dopamine D2, Dopamine Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Schizophrenia: More dopamine, more D 2 receptors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks